Phospholipase
Phospholipases are enzymes that catalyze the hydrolysis of phospholipids into fatty acids and other lipid mediators. It plays a variety of roles in tumorgenesis , inflammation and brain disorders etc.
Products Related to Phospholipase(136)
- GC12880GSK 2830371CAS: 1404456-53-6Purity: >98.50%
Orally active, allosteric inhibitor of Wip1 phosphatase
- GC10645MJ33 (lithium salt)CAS: 1007476-63-2Purity: ≥95.00%
inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6
- GC11021Bromoenol lactoneCAS: 88070-98-8Purity: >98.00%
Bromoenol lactone is potent and irreversible inhibitor of myocardial cytosolic calcium-independent phospholipase A2 (iPLA2) with an IC 50 value of 7μM.
- GC11116Thioetheramide-PCCAS: 116457-99-9Purity: >95.00%
competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2)
- GC13930N-(p-amylcinnamoyl) Anthranilic AcidCAS: 110683-10-8Purity: >98%
phospholipase A2 (PLA2) inhibitor and TRP channel blocker
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC12880 | GSK 2830371 | 1404456-53-6 | >98.50% | |
Orally active, allosteric inhibitor of Wip1 phosphatase | ||||
| GC16418 | CP-91149 | 186392-40-5 | >99.50% | |
Selective inhibitor of glycogen phosphorylase | ||||
| GC19186 | GW4869 | 6823-69-4 | >98.00% | |
GW4869 is a noncompetitive neutral sphingomyelinase(N-SMase) inhibitor with an IC50 of 1 uM. | ||||
| GC10162 | JJKK 048 | 1515855-97-6 | >98.00% | |
monoacylglycerol lipase (MAGL) inhibitor | ||||
| GC10451 | U-73122 | 112648-68-7 | >98.00% | |
U-73122 is a potent and selective phospholipase C (PLC) inhibitor with an IC 50 value of approximately 1-2.1µM. It also inhibits 5-lipoxygenase (5-LO). | ||||
| GC10565 | 7-hydroxycoumarinyl Arachidonate | 161180-11-6 | >98.00% | |
substrate for cPLA2 | ||||
| GC10645 | MJ33 (lithium salt) | 1007476-63-2 | ≥95.00% | |
inhibitor of the acidic, calcium-independent (ai)PLA2 activity of Prdx6 | ||||
| GC11021 | Bromoenol lactone | 88070-98-8 | >98.00% | |
Bromoenol lactone is potent and irreversible inhibitor of myocardial cytosolic calcium-independent phospholipase A2 (iPLA2) with an IC 50 value of 7μM. | ||||
| GC11055 | 10-Pyrene-PC | 95864-17-8 | - | |
A substrate for some PLA 2 s | ||||
| GC11073 | ML 298 hydrochloride | - | >98% | |
phospholipase D2 (PLD2) inhibitor | ||||
| GC11116 | Thioetheramide-PC | 116457-99-9 | >95.00% | |
competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2) | ||||
| GC11243 | Halopemide | 59831-65-1 | >99.50% | |
phospholipase D (PLD) inhibitor | ||||
| GC11520 | ST638 | 107761-24-0 | >98% | |
tyrosine kinase inhibitor and PLD inhibitor | ||||
| GC11631 | Melittin | 20449-79-0 | >99.00% | |
Inhibits Gs and stimulates Gi activity | ||||
| GC12361 | Darapladib | 356057-34-6 | >99.50% | |
A reversible inhibitor of Lp-PLA 2 | ||||
| GC12411 | RHC 80267 | 83654-05-1 | >98.00% | |
RHC 80267 is a potent and selective diacylglycerol lipase (DAGL) inhibitor. RHC 80267 can also inhibit cholinesterase activity (IC₅₀= 4μM), suppress cyclooxygenase (COX) activity, and inhibit phosphatidylcholine hydrolysis. | ||||
| GC12420 | MAFP | 188404-10-6 | >98.00% | |
cPLA2 and iPLA2 inhibitor, potent FAAH inhibitor | ||||
| GC13276 | Oleyloxyethyl Phosphorylcholine | 84601-19-4 | >98% | |
PLA2 inhibitor | ||||
| GC13351 | VU0359595 | 1246303-14-9 | >95.00% | |
PLD1 inhibitor | ||||
| GC13585 | YM 26734 | 144337-18-8 | >98.00% | |
Competitive inhibitor of secretory phospholipase A2 (sPLA2) | ||||
| GC13620 | FIPI | 939055-18-2 | >99.00% | |
phosholipase D (PLD) inhibitor | ||||
| GC13930 | N-(p-amylcinnamoyl) Anthranilic Acid | 110683-10-8 | >98% | |
phospholipase A2 (PLA2) inhibitor and TRP channel blocker | ||||
| GC13948 | GPi 688 | 918902-32-6 | >98% | |
glycogen phosphorylase inhibitor | ||||
| GC14090 | o-3M3FBS | 313981-55-4 | >98% | |
Inactive analog of m-3M3FBS (PLC activator) | ||||
